Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 0.00, near the high end of its 5-year range (-0.51–0.16).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 689 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Nexalin Technology, Inc.
Market Cap
$3.57M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$3.42M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$3.40M
Debt to Equity Ratio
7.21
TTM Avg
1.21
3Y Avg
0.62
5Y Avg
0.62
Market Cap
$4.00M
Debt to Equity Ratio
0.70
TTM Avg
0.62
3Y Avg
0.55
5Y Avg
2.94
Market Cap
$3.27M
Debt to Equity Ratio
0.07
TTM Avg
0.10
3Y Avg
0.11
5Y Avg
0.08
Market Cap
$4.04M
Debt to Equity Ratio
0.11
TTM Avg
0.30
3Y Avg
4.92
5Y Avg
3.36
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | $3.57M | 0.00 | 0.00 | 0.00 | 0.00 |
| Evogene Ltd. (EVGN)vs › | $3.55M | N/A | 0.69 | 0.37 | 0.26 |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | 0.00 | 0.00 | 7.00 | 4.21 |
| Eocene Ltd. (EOCN)vs › | $3.46M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Moolec Science S.A. (MLEC)vs › | $3.40M | 7.21 | 1.21 | 0.62 | 0.62 |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.00M | 0.70 | 0.62 | 0.55 | 2.94 |
| Aethlon Medical, Inc. (AEMD)vs › | $3.27M | 0.07 | 0.10 | 0.11 | 0.08 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.04M | 0.11 | 0.30 | 4.92 | 3.36 |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.25M | 0.02 | 0.06 | 0.17 | 0.12 |
Debt/Equity
0.00
Current Ratio
1.25
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.16 |
| 2023-06-30 | 0.13 |
| 2023-03-31 | 0.11 |
| 2022-12-31 | 0.14 |
| 2022-09-30 | 0.12 |
| 2022-06-30 | -0.36 |
| 2022-03-31 | -0.43 |
| 2021-12-31 | -0.51 |
| 2021-09-30 | -0.34 |
| 2021-06-30 | -0.40 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
